{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:48:57Z","timestamp":1789858137000,"version":"4.0.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T00:00:00Z","timestamp":1531267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ES101081"],"award-info":[{"award-number":["ES101081"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12969-018-0261-x","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T13:50:39Z","timestamp":1531317039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Pediatric Rheumatology Collaborative Study Group \u2013 over four decades of pivotal clinical drug research in pediatric rheumatology"],"prefix":"10.1186","volume":"16","author":[{"name":"for the PRCSG Advisory Council","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2987","authenticated-orcid":false,"given":"Hermine I.","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Kingsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Co","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayfel","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Goldmuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen B.","family":"Onel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward H.","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,11]]},"reference":[{"issue":"3","key":"261_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1542\/peds.2013-4060","volume":"133","author":"KA Neville","year":"2014","unstructured":"Neville KA, Frattarelli DA, Galinkin JL, et al. Off-label use of drugs in children. Pediatrics. 2014;133(3):563\u20137.","journal-title":"Pediatrics"},{"issue":"5","key":"261_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1586\/17512433.2013.831531","volume":"6","author":"AC Rose","year":"2013","unstructured":"Rose AC, van\u2019t Hoff W, Beresford MW, Tansey SP. NIHR medicines for children research network: improving children\u2019s health through clinical research. Expert Rev Clin Pharmacol. 2013;6(5):581\u20137.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"261_CR3","unstructured":"Best pharmaceuticals for children act of 2007. Food and Drug Administration Amendments Act (FDAAA), Title V Vol Public Law No. 110-85."},{"key":"261_CR4","first-page":"No. 108","volume-title":"Pub L","author":"Pediatric Research Equity Act","year":"2003","unstructured":"Pediatric Research Equity Act. Pub L; 2003. p. No. 108\u201355."},{"key":"261_CR5","volume-title":"Safe and effective medicines for children : pediatric studies conducted under the best Pharmaceuticals for Children act and the pediatric research equity act","author":"MJ Field","year":"2012","unstructured":"Field MJ, Boat TF, Institute of Medicine (U.S.), National Research Council (U.S.). Safe and effective medicines for children : pediatric studies conducted under the best Pharmaceuticals for Children act and the pediatric research equity act. Washington, D.C.: The National Academies Press; 2012."},{"key":"261_CR6","volume-title":"Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA)","author":"U.S. Food and Drug Administration. Guidance for Industry","year":"1999","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: Clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis (RA). 1999. https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm071579.pdf ."},{"key":"261_CR7","volume-title":"Best Pharmaceuticals for Children act and Pediatric Research Equity act - July 2016 report to congress","author":"R Califf","year":"2016","unstructured":"Califf R. Best Pharmaceuticals for Children act and Pediatric Research Equity act - July 2016 report to congress. 2016. https:\/\/www.fda.gov\/downloads\/ScienceResearch\/SpecialTopics\/PediatricTherapeuticsResearch\/UCM509815.pdf ."},{"issue":"10","key":"261_CR8","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.clinthera.2017.09.001","volume":"39","author":"MA Turner","year":"2017","unstructured":"Turner MA, Attar S, de Wildt SN, Vassal G, Mangiarini L, Giaquinto C. Roles of clinical research networks in pediatric drug development. Clin Ther. 2017;39(10):1939\u201348.","journal-title":"Clin Ther"},{"key":"261_CR9","volume-title":"Guidance for industry: pediatric study plans - content of and process for submitting initial pediatric study plans and amended initial pediatric study plans","author":"U.S. Food and Drug Administration","year":"2016","unstructured":"U.S. Food and Drug Administration. Guidance for industry: pediatric study plans - content of and process for submitting initial pediatric study plans and amended initial pediatric study plans 2016. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm360507.pdf ."},{"issue":"5","key":"261_CR10","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/01.bor.0000130286.54383.ea","volume":"16","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol. 2004;16(5):566\u201370.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"261_CR11","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/art.34343","volume":"64","author":"CA Wallace","year":"2012","unstructured":"Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012\u201321.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"261_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7326\/0003-4819-157-8-201210160-00003","volume":"157","author":"PJ Hashkes","year":"2012","unstructured":"Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533\u201341.","journal-title":"Ann Intern Med"},{"issue":"20","key":"261_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1056\/NEJM198605153142001","volume":"314","author":"EJ Brewer","year":"1986","unstructured":"Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. N Engl J Med. 1986;314(20):1269\u201376.","journal-title":"N Engl J Med"},{"issue":"4","key":"261_CR14","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/art.1780230403","volume":"23","author":"EJ Brewer Jr","year":"1980","unstructured":"Brewer EJ Jr, Giannini EH, Barkley E. Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis Rheum. 1980;23(4):404\u201311.","journal-title":"Arthritis Rheum"},{"issue":"16","key":"261_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","volume":"326","author":"E Giannini","year":"1992","unstructured":"Giannini E, Brewer E, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebocontrolled trial. N Engl J Med. 1992;326(16):1043\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"261_CR16","first-page":"140","volume":"9","author":"J Bass","year":"1982","unstructured":"Bass J, Giannini E, Brewer E, et al. Pirprofen (Rengasil) in the treatment of juvenile rheumatoid arthritis. A segment I study. J Rheumatol. 1982;9(1):140\u20133.","journal-title":"J Rheumatol"},{"issue":"1","key":"261_CR17","first-page":"123","volume":"9","author":"E Brewer","year":"1982","unstructured":"Brewer E, Giannini E, Baum J, et al. Aspirin and fenoprofen (Nalfon) in the treatment of juvenile rheumatoid arthritis results of the double blind-trial. A segment II study. J Rheumatol. 1982;9(1):123\u20138.","journal-title":"J Rheumatol"},{"issue":"1","key":"261_CR18","first-page":"129","volume":"9","author":"E Brewer","year":"1981","unstructured":"Brewer E, Giannini E, Baum J, et al. Sodium meclofenamate (Meclomen) in the treatment of juvenile rheumatoid arthritis. A segment I study. J Rheumatol. 1981;9(1):129\u201334.","journal-title":"J Rheumatol"},{"issue":"1","key":"261_CR19","first-page":"135","volume":"9","author":"E Brewer","year":"1982","unstructured":"Brewer E, Giannini E, Baum J, et al. Proquazone (Biarsan) in the treatment of juvenile rheumatoid arthritis. A segment I study. J Rheumatol. 1982;9(1):135\u20139.","journal-title":"J Rheumatol"},{"issue":"1","key":"261_CR20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3899\/jrheum.080073","volume":"36","author":"I Foeldvari","year":"2009","unstructured":"Foeldvari I, Szer IS, Zemel LS, et al. A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol. 2009;36(1):174\u201382.","journal-title":"J Rheumatol"},{"issue":"5","key":"261_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0022-3476(77)81045-7","volume":"91","author":"JE Levinson","year":"1977","unstructured":"Levinson JE, Baum J, Brewer E, et al. Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis. J Pediatr. 1977;91(5):799\u2013804.","journal-title":"J Pediatr"},{"issue":"5","key":"261_CR22","first-page":"985","volume":"33","author":"A Reiff","year":"2006","unstructured":"Reiff A, Lovell DJ, Van Adelsberg J, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension. J Rheumatol. 2006;33(5):985\u201395.","journal-title":"J Rheumatol"},{"issue":"1","key":"261_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1546-0096-12-29","volume":"12","author":"RE Sobel","year":"2014","unstructured":"Sobel RE, Lovell DJ, Brunner HI, et al. Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry. Pediatr Rheumatol. 2014;12(1):29.","journal-title":"Pediatr Rheumatol"},{"issue":"11","key":"261_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric rheumatology collaborative study group. N Engl J Med. 2000;342(11):763\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"261_CR25","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/art.24777","volume":"60","author":"EH Giannini","year":"2009","unstructured":"Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009;60(9):2794\u2013804.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"261_CR26","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096\u2013106.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"261_CR27","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320.","journal-title":"N Engl J Med"},{"issue":"9636","key":"261_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","volume":"372","author":"N Ruperto","year":"2008","unstructured":"Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(9636):383\u201391.","journal-title":"Lancet"},{"issue":"6","key":"261_CR29","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1136\/annrheumdis-2014-205351","volume":"74","author":"HI Brunner","year":"2015","unstructured":"Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110\u20137.","journal-title":"Ann Rheum Dis"},{"key":"261_CR30","doi-asserted-by":"crossref","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-P\u00e9rez N, Keltsev V. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2017:annrheumdis-2016.","DOI":"10.1136\/annrheumdis-2016-210456"},{"issue":"9","key":"261_CR31","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/art.38042","volume":"65","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2013;65(9):2486\u201396.","journal-title":"Arthritis Rheum"},{"issue":"25","key":"261_CR32","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F De Benedetti","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395.","journal-title":"N Engl J Med"},{"issue":"25","key":"261_CR33","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","volume":"367","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2396\u2013406.","journal-title":"N Engl J Med"},{"issue":"1","key":"261_CR34","first-page":"114","volume":"9","author":"EH Giannini","year":"1982","unstructured":"Giannini EH, Brewer EJ Jr. Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. II. Analysis and presentation of data. J Rheumatol. 1982;9(1):114\u201322.","journal-title":"J Rheumatol"},{"issue":"1","key":"261_CR35","first-page":"109","volume":"9","author":"EJ Brewer Jr","year":"1982","unstructured":"Brewer EJ Jr, Giannini EH. Standard methodology for segment I, II, and III pediatric rheumatology collaborative study group studies. I. Design. J Rheumatol. 1982;9(1):109\u201313.","journal-title":"J Rheumatol"},{"issue":"3","key":"261_CR36","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/art.22003","volume":"55","author":"JA Singh","year":"2006","unstructured":"Singh JA, Solomon DH, Dougados M, et al. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006;55(3):348\u201352.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"261_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1136\/ard.55.1.73","volume":"55","author":"N Ruperto","year":"1996","unstructured":"Ruperto N, Giannini EH. Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Ann Rheum Dis. 1996;55(1):73\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"261_CR38","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","volume":"40","author":"EH Giannini","year":"1997","unstructured":"Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40(7):1202\u20139.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"261_CR39","first-page":"1058","volume":"29","author":"HI Brunner","year":"2002","unstructured":"Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol. 2002;29(5):1058\u201364.","journal-title":"J Rheumatol"},{"issue":"6","key":"261_CR40","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3899\/jrheum.131503","volume":"41","author":"CA Wallace","year":"2014","unstructured":"Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41(6):1163\u201370.","journal-title":"J Rheumatol"},{"issue":"3","key":"261_CR41","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli A, Minoia F, Dav\u00ec S, et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European league against rheumatism\/American College of Rheumatology\/Paediatric rheumatology international trials organisation collaborative initiative. Arthritis Rheumatol. 2016;68(3):566\u201376.","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"261_CR42","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/1529-0131(199907)42:7<1354::AID-ANR8>3.0.CO;2-4","volume":"42","author":"HI Brunner","year":"1999","unstructured":"Brunner HI, Feldman BM, Bombardier C, Silverman ED. Sensitivity of the systemic lupus erythematosus disease activity index, British isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42(7):1354\u201360.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"261_CR43","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/art.10072","volume":"46","author":"HI Brunner","year":"2002","unstructured":"Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum. 2002;46(2):436\u201344.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"261_CR44","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/rheumatology\/keg403","volume":"42","author":"N Ruperto","year":"2003","unstructured":"Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford). 2003;42(12):1452\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"261_CR45","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/art.21230","volume":"52","author":"N Ruperto","year":"2005","unstructured":"Ruperto N, Ravelli A, Cuttica R, et al. The pediatric rheumatology international trials organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set. Arthritis Rheum. 2005;52(9):2854\u201364.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"261_CR46","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/acr.20507","volume":"63","author":"HI Brunner","year":"2011","unstructured":"Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011;63(9):1213\u201323.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"5","key":"261_CR47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/acr.21612","volume":"64","author":"R Mina","year":"2012","unstructured":"Mina R, Klein-Gitelman MS, Ravelli A, et al. Inactive disease and remission in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(5):683\u201393.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"10","key":"261_CR48","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8","volume":"42","author":"DJ Lovell","year":"1999","unstructured":"Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The childhood myositis assessment scale (CMAS): a quantitative tool for the evaluation of muscle function. The juvenile dermatomyositis disease activity collaborative study group. Arthritis Rheum. 1999;42(10):2213\u20139.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"261_CR49","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/acr.20280","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Pistorio A, Ravelli A, et al. The Paediatric rheumatology international trials organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(11):1533\u201341.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"261_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.23177","volume":"58","author":"CG Helmick","year":"2008","unstructured":"Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheumatol. 2008;58(1):15\u201325.","journal-title":"Arthritis Rheumatol"},{"key":"261_CR51","unstructured":"Boat TF, Field MJ. Rare diseases and orphan products: accelerating research and development. Washington, DC: National Academies Press; 2011."},{"issue":"7","key":"261_CR52","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3899\/jrheum.120661","volume":"40","author":"LR Harrold","year":"2013","unstructured":"Harrold LR, Salman C, Shoor S, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996\u20132009. J Rheumatol. 2013;40(7):1218\u201325.","journal-title":"J Rheumatol"},{"key":"261_CR53","unstructured":"Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2014:HYPERTENSIONAHA. 114.04035."},{"key":"261_CR54","doi-asserted-by":"crossref","unstructured":"Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). J Gastroenterol. 2017;52(10):1101\u201311.","DOI":"10.1007\/s00535-017-1326-1"},{"key":"261_CR55","doi-asserted-by":"crossref","unstructured":"Ruperto N, Brunner HI, Lovell DJ, Martini A. Extrapolation or controlled trials in paediatrics: the current dilemma. Archives of disease in childhood. 2017:archdischild-2017.","DOI":"10.1136\/archdischild-2017-312994"},{"issue":"2","key":"261_CR56","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64(2):557\u201367.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"261_CR57","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/art.20944","volume":"52","author":"S Yokota","year":"2005","unstructured":"Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti\u2013interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheumatol. 2005;52(3):818\u201325.","journal-title":"Arthritis Rheumatol"},{"key":"261_CR58","unstructured":"PRCSG \/ PRINTO. Joint Assessor certification. https:\/\/prcsg.org\/index.php\/prcsg-printo-joint-assessor-certification . Accessed 2 Jan 2018."},{"issue":"11","key":"261_CR59","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nrrheum.2016.156","volume":"12","author":"RS Yeung","year":"2016","unstructured":"Yeung RS, Albani S, Feldman BM, Mellins E, Prakken B, Wedderburn LR. Enhancing translational research in paediatric rheumatology through standardization. Nat Rev Rheumatol. 2016;12(11):684\u201390.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"261_CR60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13075-016-1212-x","volume":"19","author":"AH Brachat","year":"2017","unstructured":"Brachat AH, Grom AA, Wulffraat N, et al. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther. 2017;19(1):13.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"261_CR61","first-page":"688","volume":"26","author":"S Nielsen","year":"2008","unstructured":"Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2008;26(4):688\u201392.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"261_CR62","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/rheumatology\/keh592","volume":"44","author":"G Simonini","year":"2005","unstructured":"Simonini G, Giani T, Stagi S, de Martino M, Falcini F. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44(6):777\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"261_CR63","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/acr.20283","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010;62(11):1542\u201351.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"261_CR64","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1002\/art.39234","volume":"67","author":"DJ Lovell","year":"2015","unstructured":"Lovell DJ, Ruperto N, Mouy R, et al. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous Abatacept for up to seven years. Arthritis Rheumatol. 2015;67(10):2759\u201370.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"261_CR65","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/art.38984","volume":"67","author":"F De Benedetti","year":"2015","unstructured":"De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015;67(3):840\u20138.","journal-title":"Arthritis Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0261-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-018-0261-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-018-0261-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T06:54:51Z","timestamp":1661583291000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-018-0261-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["261"],"URL":"https:\/\/doi.org\/10.1186\/s12969-018-0261-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,11]]},"assertion":[{"value":"6 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This research review does not report on human participants, human data or human or animal experiments.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Lovell is Chairman of the PRCSG, Dr. Brunner is the Scientific Director of the PRCSG. All other named authors are members of the PRCSG Advisory Council. Drs. Yim and Peng are also members of the Advisory Council and reviewed the manuscript but deemed their contributions to the manuscript not significant enough to be included as named authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"45"}}